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I
t is generally recognized that type 2 di-
abetes is one of the major challenges of
the 21st century. Its prevalence is
growing rapidly worldwide, particularly
indevelopingcountries(1).Itremainsthe
ﬁrst cause of blindness, end-stage renal
disease, and nontraumatic lower-limb
amputation and one of the major causes
ofcardiovasculardisease(2,3).Becauseof
its high morbidity and excess mortality, it
has become a tremendous burden on
health care cost (4).
In the last decade, a number of in-
terventions have been shown to be ef-
fective in the prevention of diabetes in
high-risk populations with impaired
glucose tolerance and/or impaired fast-
ing glucose (5–7). Yet, few countries
have adopted policies for the screening
and strategies for treating subjects with
pre-diabetes. Furthermore, despite the
development of newer therapies for
treatment of diabetes, the disease is still
associated with a high incidence of mi-
croangiopathy and macrovascular com-
plications. Any new strategies that
could help to curtail the burden of dia-
betes would be greatly appreciated.
More recently, it was postulated that
early insulin replacement in type 2 diabe-
tes, and perhaps even in pre-diabetes,
may reduce cardiovascular risk and may
even offer protection for the -cell (8,9).
However, a closer look at the available
datadoesnotsupportthehypothesis.The
Outcome Reduction with an Initial
Glargine Intervention (ORIGIN) study is
still ongoing and therefore does not allow
any conclusion in pre-diabetes. In type 2
diabetes, however, the published data
support neither a beneﬁcial effect of insu-
lin therapy per se on microvascular com-
plications, nor on cardiovascular events
and mortality. In addition, the data sug-
gesting that insulin therapy can improve
the -cell response to a glucose challenge
could just as well be interpreted as being
due to the improvement in glycemic con-
trol, rather than to the insulin therapy.
And ﬁnally, we should not underestimate
the adverse events associated with insulin
treatment.
INSULIN THERAPY AND
MICROVASCULAR
COMPLICATIONS— The Kum-
amotostudywastheﬁrstprospectiveran-
domized controlled trial showing that
multiple insulin injection therapy in type
2 diabetes, compared with conventional
insulin treatment, was associated with a
signiﬁcantreductionintheonsetandpro-
gression of retinopathy, nephropathy,
andneuropathyinarelativelysmallnum-
ber (n  101) of Japanese patients with
type 2 diabetes (10). Nevertheless, the
pivotal study on the effect of glycemic
controlontheprogressionofmicrovascu-
lar complications in type 2 diabetes re-
mains the U.K. Prospective Diabetes
Study (UKPDS). In this landmark study,
4,209 newly diagnosed type 2 diabetic
patients were randomized to receive con-
ventional therapy (n  1,138) or inten-
sivetreatment(n3,071)(11,12).Those
randomized to intensive policy were fur-
ther randomized to sulfonylurea (n 
1,573)orinsulin(n1,156),andasmall
number of overweight patients were ran-
domized to metformin (n  342). Over a
10-year period, median A1C was 7.0% in
the intensive treatment group with sulfo-
nylureaandinsulin,comparedwith7.9%
in the conventional treatment group, an
absolute 0.9% reduction. There was no
differenceinA1Camongthevariousther-
apies in the intensive group. Compared
with the conventional group, the inten-
sive treatment was associated with a rela-
tive risk reduction of 12% for any
diabetes-related end points (P  0.029),
25% for microvascular end points (P 
0.0099), 21% for retinopathy at 12 years
(P  0.015), and 33% for albuminuria at
12 years (P  0.000054) (Table 1) (11).
The median A1C for the metformin treat-
ment group was 7.4% compared with
8.0% for the conventional group, a 0.6%
difference. This lower A1C was also asso-
ciated with a signiﬁcant difference in the
risk of any diabetes-related end points
(32% risk reduction; P  0.0023) (12).
Furthermore, there was a linear relation-
ship between A1C and the risk of micro-
vascular complications (Fig. 1) (13). For
any 1% reduction in A1C, there was an
estimated risk reduction of microvascular
complications of 37%. Of importance is
thattheUKPDSauthorsstatedclearlythat
“no difference in the risk reduction of mi-
crovascular clinical end points was seen
between the three intensive treatments,
and thus, improved glycemic control,
rather than any one therapy, is the prin-
cipal factor” (11). Therefore, we can con-
clude that, in the UKPDS, early insulin
treatment offered any advantage over
other therapies in the prevention of mi-
crovascular complications.
INSULIN THERAPY AND
MACROVASCULAR
COMPLICATIONS— The data sup-
porting a protective role for exogenous
insulin against cardiovascular complica-
tions is not more convincing. In fact, a
tremendous amount of literature going
back 50 years suggests that hyperinsulin-
emia and/or exogenous insulin injection
is associated with increased cardiovascu-
lardisease(14).Theﬁrststudysuggesting
that intensive insulin treatment could
have a beneﬁcial effect on cardiovascular
mortality in type 2 diabetes after myocar-
dial infarction was the Diabetes Mellitus,
Insulin Glucose Infusion in Acute Myo-
cardial Infarction (DIGAMI) 1 study (15).
In this study, 620 subjects admitted for
acute myocardial infarction and previ-
ously known to have diabetes were allo-
cated to standard treatment plus insulin-
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randomized to either multiple insulin in-
jections (intensive group) or standard
treatment (control group). After a mean
follow-upof3.4years,therewasarelative
risk reduction of 28% in the intensive in-
sulingroup(P0.011).Thereductionin
mortality was most apparent in those pa-
tients who had never been treated with
insulin before and who had a lower car-
diovascular risk (15). Nonetheless, the
DIGAMI 2 study did not conﬁrm the ﬁrst
observation that an early and acutely in-
troduced insulin therapy followed by
long-term insulin treatment improves
survival rate in type 2 diabetic patients
after myocardial infarction, compared
with conventional management (16). In
this study, 1,253 patients with type 2 di-
abetes and acute myocardial infarction
were randomly assigned to acute insulin-
glucose infusion followed by insulin-
based long-term glucose control (group
1; n  474), to insulin-glucose infusion
followed by standard glucose control
(group 2; n  473), or to routine meta-
bolic management according to local
practice (group 3; n  306). The primary
end point was all-cause mortality. These
patientswerefollowedforamedianof2.1
years, and no signiﬁcant difference was
observed in mortality rate among the
three groups. In fact, there was no differ-
ence in glycemic control between the
three groups. However, the epidemiolog-
ical analysis of the data conﬁrms that the
glycemic control was a strong and inde-
pendentpredictoroflong-termmortality.
Again,thissuggeststhatthebloodglucose
control is of importance, not the manner
in which it is achieved.
A further randomized-controlled trial
where insulin therapy in type 2 diabetes
was compared with other therapies on
cardiovasculardiseaseistheUKPDS(11).
Overall, intensive glycemic control was
associated with a 16% relative risk reduc-
tioninmyocardialinfarction(hazardratio
[HR] 0.84 [95% CI 0.71–1.0]; P 
0.052). Much has been written about the
P value of 0.052; although the purist stat-
isticians interpret this as nonsigniﬁcant,
the clinicians ﬁnd it clinically relevant.
Even then, insulin treatment did not per-
form better than the other oral agents in
the intensive group. In fact, only met-
forminasasubgroupshowedasigniﬁcant
reduction in myocardial infarction com-
pared with the conventional group (HR
0.61 [0.41–0.89]; P  0.01), but it was
not signiﬁcantly different from the other
intensive treatment, including insulin.
Furthermore, the epidemiological analy-
sisofthedatashowedalinearrelationship
between the A1C and the risk of myocar-
dial infarction (Fig. 1) (13). For any 1%
reduction in A1C, there was a 14% de-
crease in the risk of myocardial infarction
(P  0.0001). Again, this strongly sug-
geststhatglycemiccontrolisessential,in-
dependent of how it is achieved.
Interestingly, the 10-year follow-up anal-
ysis of the UKPDS showed a 9% signiﬁ-
cantreductioninmyocardialinfarctionin
the insulin and/or sulfonylurea group
(P  0.04) and a continued beneﬁt of
metformin (33%, P  0.005) (17). These
results emphasized the importance of re-
ducing blood glucose early in the disease,
independent of the antidiabetic medica-
tions used, and suggest that the beneﬁt is
long term.
Figure 1—The relationship between A1C and the incidence of microvascular end points and
myocardial infarction. Reproduced with permission from Stratton et al. (13).
Table 1—Effect of intensive glycemic control with sulfonylurea or insulin on diabetes-related
complications
Relative risk
reduction (%) End points P
12 Any diabetes-related end point 0.029
25 Microvascular end points 0.0099
16 Myocardial infarction 0.052
24 Cataract extraction 0.046
21 Retinopathy at 12 years 0.015
33 Albuminuria at 12 years 0.000054
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THE -CELL— Garvey et al. (18)
published an elegant study of 14 poorly
controlled type 2 diabetic patients sub-
mitted to intensive insulin therapy. All
patientsweresubmittedtoanintravenous
glucose tolerance test before and after 3
weeks of intensive treatment with contin-
uoussubcutaneousinsulininfusion.After
achieving near-normal plasma glucose,
continuous subcutaneous insulin infu-
sionresultedinasigniﬁcantimprovement
in the ﬁrst- and second-phase insulin se-
cretion, as well as in C-peptide in re-
sponse to the intravenous glucose
challenge (P0.01). This was conﬁrmed
by Ryan et al. (19) in 16 newly diagnosed
type 2 diabetic patients put on 2–3 weeks
of intensive insulin therapy, followed up
for 1 year. There was a major improve-
ment in the glucose proﬁle in response to
a 75-g oral glucose tolerance test (OGTT)
and a small but signiﬁcant improvement
in insulin response immediately after the
short-term intensive insulin therapy. At 1
year, good glycemic control was main-
tained and insulin response to an OGTT
was further improved (P  0.01).
However, Kolterman et al. (20)
showed similar observations in type 2 di-
abetes treated intensively with glyburide.
In 17 patients, serum glucose and insulin
levels were measured at hourly intervals
throughout the day, during which they
had a standardized breakfast and lunch.
This assessment was carried out before
and after 3 months of glyburide therapy.
The fasting and the postprandial serum
glucose levels were signiﬁcantly reduced
after 3 months of therapy (P  0.02 and
P  0.001, respectively). Although the
fasting serum levels were not signiﬁcantly
different, the postprandial insulin levels
were signiﬁcantly increased in response
to the standardized meals after 3 months
ofglyburidetreatment(P0.001).Inter-
estingly, Kosaka et al. (21), as early as
1980, had already shown that after inten-
sive treatment in poorly controlled type 2
diabetic patients, the improvement in in-
sulin response to a glucose challenge was
independent of the mode of treatment.
Eighty-nine poorly controlled patients
with type 2 diabetes who attended the
outpatient clinic were treated with either
dietalone(n28),sulfonylureaplusdiet
(n  48), or insulin plus diet (n  13).
Theywereallsubmittedtoa100-gOGTT
before treatment and after 6 months of
intensive therapy; for the insulin-treated
group,however,theOGTTwasdoneafter
2weeksoftreatmenttoavoidinterference
withinsulinantibodiesintheradioimmu-
noassay. The degree of improvement of
insulin response to the OGTT was similar
among the three treatment groups, and
the glucose tolerance curves were im-
proved to a similar extent (Fig. 2) (21).
It is therefore concluded that inten-
sive glucose treatment in type 2 diabetes
will improve the -cell response to a glu-
cose challenge independently of the an-
tidiabetic medication used. It is believed
that this is due to a reduction in glucose
toxicity at the -cell level.
INSULIN THERAPY AND ITS
ADVERSE EVENTS— Hypoglyce-
mia is considered to occur less frequently
in type 2 diabetes than in type 1 diabetes.
However, in recent years, the pursuit of
strict glycemic control in type 2 diabetes
hasencouragedtheearlierintroductionof
insulin and the use of more intensive reg-
imens. This is bound to have a signiﬁcant
impact on the risk of hypoglycemia in
these patients. Again, the pivotal study is
the UKPDS (11). In this population with
newly diagnosed type 2 diabetes, the in-
cidence of any hypoglycemic event in in-
sulin-treated newly diagnosed type 2
diabetic patients was 36.5 per 100 pa-
tient-years, at least twice as frequent as in
Figure2—Changesinbloodglucose(BG)andplasmainsulin(immunoreactiveinsulin[IRI])duringa100-gglucosetolerancetestbeforeandafter
treatmentwithdietonly,sulfonylurea(SU),orinsulinofovertlydiabeticpatients(meanSD)accordingtotheinitialsumofbloodglucose.Number
in parentheses indicates number of patients before treatment (F) and after treatment (E). Reproduced with permission from Kosaka et al. (21).
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the incidence of severe hypoglycemia was
muchlowerthanintype1diabetes,itwas
still 2.3 per 100 patient-years, a four- to
sixfold increase compared with the sul-
fonylurea-treated group. Even more
disturbing is that the risk of severe hy-
poglycemia is far greater with increasing
duration of diabetes and insulin therapy.
Henderson et al. (22) observed that in
thosetype2diabeticpatientstreatedwith
insulin for over 10 years, the estimated
incidence of severe hypoglycemia was 28
episodes per 100 patient-years (Fig. 3).
This is nearly half the rate documented
during intensive insulin therapy in type
1 diabetes in the Diabetes Control and
ComplicationsTrial(23).Theriskofse-
vere hypoglycemia should not be un-
derestimated. This does not indicate
that we should not start insulin in a
timely fashion. But we should try to
minimize the occurrence of severe
hypoglycemia.
In the UKPDS, intensive insulin ther-
apy was associated with a 5-kg weight
gain (11), and this is not just a cosmetic
problem. Weight gain is also associated
with an increase in cardiovascular risk
factors, such as hypertension and dyslip-
idemia (24). Meigs et al. (24) observed
that in 638 obese subjects with the meta-
bolic syndrome, the adjusted risk for car-
diovasculardiseasewas2.13(1.43–3.18).
Furthermore, 6.8% weight loss in type 2
diabetesresultedinasigniﬁcantimprove-
ment of cardiovascular risk factors, such
as dyslipidemia and hypertension (25).
Finally, in vitro, in vivo, and epidemio-
logical studies suggest that there is a link
between insulin concentration and the
risk of colorectal cancer. Insulin has been
shown to be a growth factor and to stim-
ulate the growth of colorectal cancer pre-
cursor cells in animals (26). Clinical
studies have shown that high circulating
insulin levels are independent predictors
ofcolorectalcancer(27).Inaddition,type
2 diabetes, a condition associated with
hyperinsulinemia, has a 30–40% in-
creased risk of colorectal cancer (28).
When endogenous insulin declines, most
of these patients will require exogenous
insulin injection, thus perpetuating hy-
perinsulinemia (18). More recently, Yang
et al. (29). conducted a retrospective
nested case-control study of all patients
with a diagnosis of type 2 diabetes (n 
24,918) in the General Practice Research
Database from the U.K. between June
1987 and April 2002 and performed fol-
low-up over time for the occurrence of
colorectal cancer. The incidence of colo-
rectal cancer in insulin users (n  3,160)
was 197 per 100,000 person-years, com-
paredwith124perperson-yearsintype2
diabetic subjects not receiving insulin
(n  21,758). The age- and sex-adjusted
HR of colorectal cancer associated with
1 year of insulin use was 2.1 (95% CI
1.2–3.4; P  0.005). The odds ratio (OR)
for each incremental year of insulin ther-
apywasanincreasedriskof1.21(95%CI
1.03–1.42; P  0.02). After 5 years of
insulin therapy, the OR was 4.7 (95% CI
1.3–16.7; P  0.02) (Fig. 4). It was con-
cludedthatthechronicuseofinsulinmay
increase the risk of colorectal cancer in
type 2 diabetic patients (29). Of course,
thisobservationdoesnotconﬁrmacause-
and-effect relationship.
CONCLUSIONS — Current evidence
clearly indicates that achieving normo-
glycemia reduces the risk of microvas-
cular complications and strongly
suggests that this is probably true also
for cardiovascular complications. There
is no reliable evidence at the present
time to indicate that the earlier use of
insulin provides any additional long-
term beneﬁt beyond glycemic control.
In addition, insulin therapy is associ-
ated with adverse effects including hy-
poglycemia, weight gain, and probably
increased risk of colorectal cancer.
However, treating to target remains the
crucialgoal.Insulinmustbeintroduced
inatimelyfashion,thatis,assoonasthe
oral antidiabetic agents fail to maintain
A1C 7.0%.
Figure 3—The prevalence of severe hypoglycemia in relation to the duration of type 2 diabetes.
Adapted from Henderson et al. (22).
Figure 4—The relative risk of colorectal cancer in relation to the duration of insulin therapy in
type 2 diabetes. Adapted from Yang et al. (29).
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